Myeloma Trial, Recruiting (NCT05737732)

Myeloma Trial, Recruiting NCT05737732 Sponsor: Icahn School of Medicine at Mount Sinai Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT05737732 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with Multiple Myeloma (a type of blood cancer)
People who are scheduled to have their first Autologous Stem Cell Transplant (a procedure using the patient's own stem cells)
People who are 21 years of age or older
People who are able to give their informed consent to participate
People who are proficient in English

Who may not be able to join:

People who have previously had an Autologous Stem Cell Transplant
People who are currently pregnant
People who have eye conditions that affect their ability to process light
People who have been diagnosed with a second (separate) cancer within the last 5 years
People who have a severe sleep disorder
People who have a history of bipolar disorder or manic episodes
People who have a severe psychological or mental health condition
People who have previously used light therapy
People who currently have an active infection, including COVID-19

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mariana Figueiro, PhD, Icahn School of Medicine at Mount Sinai

Phone: 518 242-4603

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05737732

Sponsor: Icahn School of Medicine at Mount Sinai

Phase: Not Applicable

Status: Recruiting

Condition: Myeloma

Trial contact: 518 242-4603

More information: https://clinicaltrials.gov/study/NCT05737732

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with Multiple Myeloma (a type of blood cancer)
People who are scheduled to have their first Autologous Stem Cell Transplant (a procedure using the patient's own stem cells)
People who are 21 years of age or older
People who are able to give their informed consent to participate
People who are proficient in English

Who may not be able to join:

People who have previously had an Autologous Stem Cell Transplant
People who are currently pregnant
People who have eye conditions that affect their ability to process light
People who have been diagnosed with a second (separate) cancer within the last 5 years
People who have a severe sleep disorder
People who have a history of bipolar disorder or manic episodes
People who have a severe psychological or mental health condition
People who have previously used light therapy
People who currently have an active infection, including COVID-19

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Icahn School of Medicine at Mount Sinai

Registry

ClinicalTrials.gov

Start date

13 February 2023

Est. completion

30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Changes in Urinary Melatonin

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov